Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

In first interview as FDA oncology chief, Angelo de Claro vows to 'continue the innovation ...

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

Angelo de Claro, the new FDA Oncology Center of Excellence director, aims to advance cancer drug regulation by integrating AI in reviews, streamlining drug development, and increasing patient trial participation. He commits to building on his predecessor's legacy while enhancing efficiency and regulatory frameworks.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You face faster FDA oncology reviews now that AI frameworks and early application communications speed decisions. Prioritise your regulatory strategy around the Oncology Center of Excellence’s renewed focus on innovation and trial enrolment.

◆ Coverage

1 source · 11 Sep 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfdaoncologydrug-approvalai-integrationclinical-trials